| |
Univariate analysis
|
Multivariate analysis
|
|---|
| |
No blasts (n = 24)
|
Residual blasts (n = 33)
|
Crude OR (95% CI)
|
P value
|
Adjusted OR (95% CI)
|
P value
|
|---|
|
Age (months)
|
53 (37–71)
|
74 (50–148)
|
1.01 (1.00–1.02)
|
0.074
|
1.008 (0.996–1.019)
|
0.18
|
|
Height (cm)
|
99.2 (91.2–110)
|
125 (103–149)
|
1.04 (1.01–1.07)
|
0.013
| | |
|
Weight (kg)
|
16.3 (12.9–20.2)
|
19.8 (16–35)
|
1.05 (1.00–1.10)
|
0.053
| | |
|
Gender (male) (%)
|
9 (37.5)
|
20 (60.6)
|
0.45 (0.15–1.33)
|
0.67
| | |
| ASA-PS≧III (%) |
2 (8.3)
|
2 (6.1)
|
0.66 (0.086–5.02)
|
0.53
| | |
|
Operation time (min)
|
29 (23–47)
|
27 (22–30)
|
0.97 (0.93–1.01)
|
0.15
| | |
|
Anesthesia time (min)
|
83 (73–92)
|
83 (74–92)
|
0.99 (0.97–1.01)
|
0.45
| | |
|
Anesthesia method (sevoflurane) (%)
|
12 (50.0)
|
7 (21.2)
|
0.27 (0.085–0.86)
|
0.045
|
2.31 (0.70–7.65)
|
0.17
|
|
WBC > 50,000/μL at diagnosis (%)
|
2 (8.3)
|
8 (24.2)
|
3.23 (0.619–16.9)
|
0.18
| | |
|
Central nervous invasion (%)
|
1 (4.2)
|
5 (15.2)
|
3.79 (0.413–34.8)
|
0.39
| | |
|
Mediastinal invasion (%)
|
0 (0)
|
0 (0)
| | | | |
|
Hypodiploid (%)
|
1 (4.2)
|
0 (0)
|
0.393 (0.284–0.554)
|
0.40
| | |
|
Genetic risk (%)
|
1 (4.2)
|
6 (18.2)
|
4.714 (0.528–42.10)
|
0.22
| | |
- Data are expressed as median (25th–75th percentile) or n (%). Residual blast cells: leukemic blast cell count in peripheral blood on day 8 following prednisone chemotherapy > 0/μL. Hypodiploid: fewer than 45 chromosomes. Genetic risk: Evidence of MLL-AF4, MLL reconstitution and/or E2A-HLF
- OR odds ratio, CI confidence interval, ASA-PS American Society of Anesthesiologists physical status, WBC white blood cell count
